| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8269128 | MAYNE PHARMA | Vacuum switch tube |
May, 2026
(2 years from now) | |
| US8629128 | MAYNE PHARMA | Vitamin formulation |
May, 2026
(2 years from now) | |
| US8263580 | MAYNE PHARMA | Vitamin formulation |
May, 2028
(4 years from now) | |
Sorilux is owned by Mayne Pharma.
Sorilux contains Calcipotriene.
Sorilux has a total of 3 drug patents out of which 0 drug patents have expired.
Sorilux was authorised for market use on 06 October, 2010.
Sorilux is available in aerosol, foam;topical dosage forms.
Sorilux can be used as use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 4 years and older, use of a calcipotriene containing foam for the treatment of psoriasis.
The generics of Sorilux are possible to be released after 07 May, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Nov 05, 2022 |
| New Dosage Form(NDF) | Oct 06, 2013 |
| New Indication(I-657) | Sep 27, 2015 |
Drugs and Companies using CALCIPOTRIENE ingredient
Market Authorisation Date: 06 October, 2010
Treatment: Use of a calcipotriene containing foam for the treatment of psoriasis; Use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 4 years and older
Dosage: AEROSOL, FOAM;TOPICAL
SORILUX family patents
